NCT00848926 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma (NCT00848926)

Trial Description
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (also known as SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

This trial is sponsored by Millennium Pharmaceuticals/Seattle Genetics. [1]

Study Data

Study Schematic

Screen Shot 2016-07-18 at 4.58.05 PM

Click here to Return to Drug map


Last Editorial review: July 18, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.